TiGenix : presenting at Key Conferences - Spring 2012
(Thomson Reuters ONE) -
Regulated information
May 8, 2012
TiGenix to Present at Key Conferences
Spring 2012
Leuven (BELGIUM) - May 8, 2012 - TiGenix (NYSE Euronext: TIG), a leader in the
field of cell therapy, announced today that during the months of May and June
the company will present at a number of key events in Europe and the U.S. geared
at investor, industry, and academic audiences to highlight the commercial
potential of ChondroCelect®, the only approved cell therapy in Europe, and of
the company's innovative proprietary allogeneic stem cell platform with programs
in Phase I, II, and III for a range of inflammatory and autoimmune diseases.
May 15-16
BioEquity, Marriott Hotel, Frankfurt, Germany
Presenter: Eduardo Bravo, CEO
Date & time: Tuesday, May 15, 16:00-16:25
Room: Level 1, Room Gold 1
May 21-23
World Stem Cells and Regenerative Medicine Congress, Victoria Park Plaza,
London, UK
Presenter: Eduardo Bravo, CEO
Date & time: Monday, May 21, 15:25 -15:50
Title: Cell Therapy & Regenerative Medicine - Progressing into phase III with an
orphan indication
May 24
Knowledge for Growth, ICC Ghent, Belgium
Presenter: Eduardo Bravo, CEO
Time: 11:30
Keynote speech - Advanced therapies: this time it is for real
June 5-8
18(th) International Stem Cell Therapy Sociey Annual Meeting, Sheraton Seattle,
WA, U.S.
Presenter: Eduardo Bravo, CEO
Date & time: June 7, 13:45-15:15
Title: Plenary Session 4 - Regenerative Medicine and Positioning for Commercial
Success - Lessons from the commercial roll out of ChondroCelect in Europe
June 18-21
BIO International Convention, Boston Convention & Exhibition Center, MA, U.S.
Presenter: Eduardo Bravo, CEO
Date & time: June 20, 15:00-15:45
Title: Stem Cell Therapies...Fact or Fiction?
June 23
VFB Biotech Congres, Leuven, Belgium
Location: Imec, Kapeldreef 75, Leuven
Presenter: Gil Beyen, Chief Business Officer
Time: 11am
June 23
Dag van de Biotechnologie, Leuven, Belgium
Location: TiGenix headquarters, Leuven
Event: Open day event throughout Flanders for all biotech companies & academic
labs
Time: 10am-5pm
For more information:
Eduardo Bravo
Chief Executive Officer
eduardo.bravo(at)tigenix.com
Claudia D'Augusta
Chief Financial Officer
claudia.daugusta(at)tigenix.com
Hans Herklots
Director Investor & Media Relations
hans.herklots(at)tigenix.com
+32 16 39 60 97
About TiGenix
TiGenix NV (NYSE Euronext Brussels: TIG) is a leading European cell therapy
company with a marketed product for cartilage repair, ChondroCelect(®), and a
strong pipeline with clinical stage allogeneic adult stem cell programs for the
treatment of autoimmune and inflammatory diseases. TiGenix is based out of
Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen
(the Netherlands). For more information please visit www.tigenix.com.
Forward-looking information
This document may contain forward-looking statements and estimates with respect
to the anticipated future performance of TiGenix and the market in which it
operates. Certain of these statements, forecasts and estimates can be recognised
by the use of words such as, without limitation, "believes", "anticipates",
"expects", "intends", "plans", "seeks", "estimates", "may", "will" and
"continue" and similar expressions. They include all matters that are not
historical facts. Such statements, forecasts and estimates are based on various
assumptions and assessments of known and unknown risks, uncertainties and other
factors, which were deemed reasonable when made but may or may not prove to be
correct. Actual events are difficult to predict and may depend upon factors that
are beyond TiGenix' control. Therefore, actual results, the financial condition,
performance or achievements of TiGenix, or industry results, may turn out to be
materially different from any future results, performance or achievements
expressed or implied by such statements, forecasts and estimates. Given these
uncertainties, no representations are made as to the accuracy or fairness of
such forward-looking statements, forecasts and estimates. Furthermore, forward-
looking statements, forecasts and estimates only speak as of the date of the
publication of this document. TiGenix disclaims any obligation to update any
such forward-looking statement, forecast or estimates to reflect any change in
TiGenix' expectations with regard thereto, or any change in events, conditions
or circumstances on which any such statement, forecast or estimate is based,
except to the extent required by Belgian law.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: TiGenix via Thomson Reuters ONE
[HUG#1609604]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 08.05.2012 - 01:01 Uhr
Sprache: Deutsch
News-ID 1111494
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Leuven
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 60 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TiGenix : presenting at Key Conferences - Spring 2012
"
steht unter der journalistisch-redaktionellen Verantwortung von
TiGenix (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
